Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Net Cash Flow (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Net Cash Flow for 6 consecutive years, with $2.4 million as the latest value for Q4 2018.

  • Quarterly Net Cash Flow rose 190.98% to $2.4 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2018, up 320.73% year-over-year, with the annual reading at -$693000.0 for FY2025, 84.5% up from the prior year.
  • Net Cash Flow hit $2.4 million in Q4 2018 for Armata Pharmaceuticals, up from -$2.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $10.0 million in Q1 2015 to a low of -$3.9 million in Q1 2014.
  • Historically, Net Cash Flow has averaged -$896650.0 across 5 years, with a median of -$2.5 million in 2015.
  • Biggest five-year swings in Net Cash Flow: tumbled 2641.26% in 2014 and later soared 356.22% in 2015.
  • Year by year, Net Cash Flow stood at -$3.2 million in 2014, then rose by 26.15% to -$2.4 million in 2015, then soared by 173.68% to $1.7 million in 2016, then plummeted by 248.68% to -$2.6 million in 2017, then surged by 190.98% to $2.4 million in 2018.
  • Business Quant data shows Net Cash Flow for ARMP at $2.4 million in Q4 2018, -$2.1 million in Q3 2018, and -$2.1 million in Q2 2018.